CAI Caris Life Sciences Inc.

Price (delayed)

$17.23

Market cap

$4.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.27

Enterprise value

$4.43B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 68

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and ...

Highlights
Caris Life Sciences's gross profit has surged by 197% YoY and by 16% QoQ
The net income has soared by 150% from the previous quarter and by 112% YoY
Caris Life Sciences's EPS has plunged by 95% from the previous quarter but it has increased by 40% YoY
The quick ratio fell by 11% QoQ

Key stats

What are the main financial stats of CAI

CAI stock price

How has the Caris Life Sciences stock price performed over time
Intraday
11.3%
1 week
3.36%
1 month
-7.81%
1 year
N/A
YTD
-36.14%
QTD
-3.64%

Financial performance

How have Caris Life Sciences's revenue and profit performed over time
Revenue
$907.29M
Gross profit
$623.45M
Operating income
$106.19M
Net income
$33.98M
Gross margin
68.7%
Net margin
3.7%
Caris Life Sciences's gross profit has surged by 197% YoY and by 16% QoQ
The net income has soared by 150% from the previous quarter and by 112% YoY
The operating income has soared by 148% YoY
CAI's net margin has soared by 144% since the previous quarter and by 106% year-on-year

Price vs fundamentals

How does CAI's price correlate with its fundamentals

Growth

What is Caris Life Sciences's growth rate over time

Valuation

What is Caris Life Sciences stock price valuation
P/E
N/A
P/B
8.2
P/S
5.37
EV/EBIT
48.84
EV/EBITDA
37.93
EV/Sales
4.88
Caris Life Sciences's EPS has plunged by 95% from the previous quarter but it has increased by 40% YoY
CAI's equity has surged by 123% year-on-year and by 2.8% since the previous quarter
CAI's price to book (P/B) is 48% lower than its last 4 quarters average of 14.1
CAI's revenue has soared by 101% YoY and by 12% from the previous quarter
CAI's P/S is 30% lower than its last 4 quarters average of 6.9

Efficiency

How efficient is Caris Life Sciences business performance
CAI's ROIC has soared by 135% YoY
Caris Life Sciences's ROS has soared by 121% YoY
Caris Life Sciences's return on assets has surged by 69% YoY and by 39% QoQ

Dividends

What is CAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CAI.

Financial health

How did Caris Life Sciences financials performed over time
Caris Life Sciences's total assets is 104% more than its total liabilities
CAI's total liabilities is down by 12% year-on-year but it is up by 3.7% since the previous quarter
The quick ratio fell by 11% QoQ
CAI's debt is 36% smaller than its equity
CAI's equity has surged by 123% year-on-year and by 2.8% since the previous quarter
The debt to equity has declined by 3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.